Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.
Trial ID: NCT06607471
Status: RECRUITING
Study type: OBSERVATIONAL
Start date: 2018-01-30
Completion date: 2035-12-31
Sponsor: Scientific Institute San Raffaele
Conditions: Non-ischemic Cardiomyopathy; Dilated Cardiomyopathy (DCM); Hypertrophic Cardiomyopathy (HCM); Restrictive Cardiomyopathy; Arrhythmogenic Cardiomyopathy (AC, ARVD/C); Left Ventricular Noncompaction; Arrhythmogenic Mitral Valve Prolapse; Peripartum Cardiomyopathy; Anderson-Fabry Disease; Arrhythmic and Inflammatory Non-ischemic Cardiomyopathy; Inflammatory (Non-Arrhythmic) Non-ischemic Cardiomyopathy; Nonischemic Cardiomyopathy Sensu Strictu (Non-inflammatory, Non-arrhythmic); Major Ventricular Arrhythmias, I.e. Sustained Ventricular Tachycardia, Ventricular Fibrillation, or Appropriate Therapy of Cardiac Device (defibrillators); Overlapping Phenotype; Undefined Phenotypes
Interventions: Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation; Support treatment, cardiac medical treatment, aetiology-specific treatment
Locations: IRCCS San Raffaele Scientific Institute
Countries: Italy
Enrollment: 15000
Age range: 18 Years - None
Sex: ALL

Summary:
Non-ischemic cardiomyopathies (NICM) represent a heterogeneous group of pathologies characterized by absence of obstructive disease of the epicardial coronary vessels and distinct structural and functional changes of the myocardium. The main identified forms include dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), and arrhythmogenic cardiomyopathy proper (ACM). More recently, further forms of cardiomyopathy have been described, less common and not uniquely classifiable, including: uncompressed myocardium (LVNC), peripartum cardiomyopathy (PPCM), structural correlates of arrhythmogenic mitral valve prolapse (AMVP), Anderson-Fabry disease (AFD), NICM associated with multi- system neuromuscular or autoimmune diseases, lysosomal diseases, glycogenosis, mitochondrial cytopathies and canal diseases with structural substrates. Finally, there are "overlap" forms, characterized by the sharing in the same subject of characteristic aspects of two or more of the above- mentioned diseases; and of the "undefined" forms, which to date do not reach the diagnostic criteria for any of the above-mentioned diseases.

To the best of current knowledge, there are two points discovered in scientific research, namely the description of the arrhythmogenic and "inflammatory" phenotypes in a broad sense, which are summarized here with the acronym AINICM. In detail:

1. Arrhythmic manifestations account for the arrhythmogenic component of AINICM, which is not limited to ACM proper. In fact, most of the above diseases have a non-arrhythmic clinical presentation and a prevailing tendency to evolve towards a picture of cardiovascular decompensation. Although sudden arrhythmic death has been described throughout the spectrum of AINICM, early arrhythmic manifestations of such diseases have an unknown prevalence, an uncertain association with different disease genotypes and phenotypes, and still uncertain predictivity of long-term arrhythmic risk. At the same time, optimal diagnostic and therapeutic pathways in arrhythmias associated with AINICM are still being studied.
2. Myocardial inflammation (M-Infl) accounts for the inflammatory component of AINICM, and has recently been described in association with many AINICM on a genetic basis, including undefined and arrhythmic forms. The data is of high interest not only in the diagnostic, but also in prognostic and therapeutic field. In fact, on the one hand the presence of M-Infl seems to have a physio- pathological role in AINICM; on the other, as already known in myocarditis, the optimal therapeutic paths of arrhythmias may differ in patients with and without M-Infl; in particular, also in the light of the preliminary data available in adult and paediatric AINICM, the inflammatory forms are expected to respond better to immunosuppressive therapy, the arrhythmogenic ones to an ablative therapy with frequent need of implantation of cardiac devices.

Based on the clinical presentation, NICM patients will be divided into arrhythmic (AINICM) and non-arrhythmic patients as study and control groups , respectively. The AINICM group will include presentation with ventricular fibrillation (VF), either sustained or non-sustained ventricular tachycardia (VT; NSVT), frequent premature ventricular complexes (PVC), supraventricular arrhythmias (SVA) and bradyarrhythmias (BA). Clinical presentations other than arrhythmic, including chest pain and heart failure, will define the control group. In parallel, as shown in Figure 1, patients with any evidence of M-Infl will be compared with those showing no signs of M-Infl.

Eligibility criteria:
Inclusion Criteria:

* Written informed consent. For pediatric patients, consent will be obtained by parents, according to the laws applicable in each of the participating countries.
* Clinical suspicion of NICM, and/or proven diagnosis of any NICM and/or genotype consistent with any NICM.

NICMs will include but not limit to: DCM, HCM, RCM, ACM, inflammatory, infiltrative, dysmetabolic, mitochondrial, toxic, neuromuscular, rheumatologic/autoimmune cardiomyopathies, channelopathies with structural substrates, LVNC, PPCM, AMVP, AFD, athlete's heart, undefined and overlap cardiomyopathies. Additional diseases of the NICM spectrum will be included in parallel with the advance of the current knowledge.

Exclusion Criteria:

* Absent informed consent.
* Proven diagnosis of cardiac disease alternative to NICM.
* Lack of diagnostic workup suitable for diagnosing NICM, detecting arrhythmias, or detecting M-Infl.
* For patients retrospectively enrolled: lack of active status of follow-up at the enrolling center.

Outcomes:
Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in DCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in HCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in RCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in ACM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in LVNC; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AMVP; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in PPCM; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in AFD; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in storage and dysmetabolic diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in mitochondrial diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in channelopathies with structural changes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in overlapping phenotypes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes; Assessment of diagnostic accuracy (in terms of true/false positive/negative rates) amongst different diagnostic techniques in undefined phenotypes; Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in DCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in HCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in RCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in ACM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in LVNC, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in AMVP, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in PPCM, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in AFD, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in mitochondrial diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in channelopathies with structural changes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in overlapping phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of M-Inf in undefined phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in DCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in HCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in RCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in ACM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in LVNC, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in AMVP, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in PPCM, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in AFD, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in storage and dysmetabolic diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in mitochondrial diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in channelopathies with structural changes, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of arrhythmogenic substrates in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases, as defined by multimodal diagnostic workup; Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of overlapping phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup; Assessment of prevalence of undefined phenotypes, as defined by multimodal diagnostic workup; Identification of DCM-specific signatures; Identification of DCM-specific signatures; Identification of DCM-specific signatures; Identification of DCM-specific signatures; Identification of DCM-specific signatures; Identification of DCM-specific signatures; Identification of DCM-specific signatures; Identification of HCM-specific signatures; Identification of HCM-specific signatures; Identification of HCM-specific signatures; Identification of HCM-specific signatures; Identification of HCM-specific signatures; Identification of HCM-specific signatures; Identification of HCM-specific signatures; Identification of RCM-specific signatures; Identification of RCM-specific signatures; Identification of RCM-specific signatures; Identification of RCM-specific signatures; Identification of RCM-specific signatures; Identification of RCM-specific signatures; Identification of RCM-specific signatures; Identification of ACM-specific signatures; Identification of ACM-specific signatures; Identification of ACM-specific signatures; Identification of ACM-specific signatures; Identification of ACM-specific signatures; Identification of ACM-specific signatures; Identification of ACM-specific signatures; Identification of LVNC-specific signatures; Identification of LVNC-specific signatures; Identification of LVNC-specific signatures; Identification of LVNC-specific signatures; Identification of LVNC-specific signatures; Identification of LVNC-specific signatures; Identification of LVNC-specific signatures; Identification of AMVP-specific signatures; Identification of AMVP-specific signatures; Identification of AMVP-specific signatures; Identification of AMVP-specific signatures; Identification of AMVP-specific signatures; Identification of AMVP-specific signatures; Identification of AMVP-specific signatures; Identification of PPCM-specific signatures; Identification of PPCM-specific signatures; Identification of PPCM-specific signatures; Identification of PPCM-specific signatures; Identification of PPCM-specific signatures; Identification of PPCM-specific signatures; Identification of PPCM-specific signatures; Identification of AFD-specific signatures; Identification of AFD-specific signatures; Identification of AFD-specific signatures; Identification of AFD-specific signatures; Identification of AFD-specific signatures; Identification of AFD-specific signatures; Identification of AFD-specific signatures; Identification of storage and dysmetabolic diseases-specific signatures; Identification of storage and dysmetabolic diseases-specific signatures; Identification of storage and dysmetabolic diseases-specific signatures; Identification of storage and dysmetabolic diseases-specific signatures; Identification of storage and dysmetabolic diseases-specific signatures; Identification of storage and dysmetabolic diseases-specific signatures; Identification of storage and dysmetabolic diseases-specific signatures; Identification of mitochondrial diseases-specific signatures; Identification of mitochondrial diseases-specific signatures; Identification of mitochondrial diseases-specific signatures; Identification of mitochondrial diseases-specific signatures; Identification of mitochondrial diseases-specific signatures; Identification of mitochondrial diseases-specific signatures; Identification of mitochondrial diseases-specific signatures; Identification of channelopathies with structural changes-specific signatures; Identification of channelopathies with structural changes-specific signatures; Identification of channelopathies with structural changes-specific signatures; Identification of channelopathies with structural changes-specific signatures; Identification of channelopathies with structural changes-specific signatures; Identification of channelopathies with structural changes-specific signatures; Identification of channelopathies with structural changes-specific signatures; Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures; Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures; Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures; Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures; Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures; Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures; Identification of cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases-specific signatures; Identification of overlapping phenotypes-specific signatures; Identification of overlapping phenotypes-specific signatures; Identification of overlapping phenotypes-specific signatures; Identification of overlapping phenotypes-specific signatures; Identification of overlapping phenotypes-specific signatures; Identification of overlapping phenotypes-specific signatures; Identification of overlapping phenotypes-specific signatures; Identification of undefined phenotypes-specific signatures; Identification of undefined phenotypes-specific signatures; Identification of undefined phenotypes-specific signatures; Identification of undefined phenotypes-specific signatures; Identification of undefined phenotypes-specific signatures; Identification of undefined phenotypes-specific signatures; Identification of undefined phenotypes-specific signatures; Differences in incidence of major events during follow-up in different NICMs; Differences in incidence of major events during follow-up in different NICMs; Differences in incidence of major events during follow-up in different NICMs; Differences in incidence of major events during follow-up in different NICMs; Differences in incidence of major events during follow-up in different NICMs; Differences in incidence of major events during follow-up in different NICMs; Differences in incidence of major events during follow-up in different NICMs; Occurrence of major cardiac events in DCM; Occurrence of major cardiac events in DCM; Occurrence of major cardiac events in DCM; Occurrence of major cardiac events in DCM; Occurrence of major cardiac events in DCM; Occurrence of major cardiac events in DCM; Occurrence of major cardiac events in DCM; Occurrence of major cardiac events in DCM; Occurrence of major cardiac events in HCM; Occurrence of major cardiac events in HCM; Occurrence of major cardiac events in HCM; Occurrence of major cardiac events in HCM; Occurrence of major cardiac events in HCM; Occurrence of major cardiac events in HCM; Occurrence of major cardiac events in HCM; Occurrence of major cardiac events in HCM; Occurrence of major cardiac events in RCM; Occurrence of major cardiac events in RCM; Occurrence of major cardiac events in RCM; Occurrence of major cardiac events in RCM; Occurrence of major cardiac events in RCM; Occurrence of major cardiac events in RCM; Occurrence of major cardiac events in RCM; Occurrence of major cardiac events in RCM; Occurrence of major cardiac events in ACM; Occurrence of major cardiac events in ACM; Occurrence of major cardiac events in ACM; Occurrence of major cardiac events in ACM; Occurrence of major cardiac events in ACM; Occurrence of major cardiac events in ACM; Occurrence of major cardiac events in ACM; Occurrence of major cardiac events in ACM; Occurrence of major cardiac events in LVNC; Occurrence of major cardiac events in LVNC; Occurrence of major cardiac events in LVNC; Occurrence of major cardiac events in LVNC; Occurrence of major cardiac events in AMVP; Occurrence of major cardiac events in AMVP; Occurrence of major cardiac events in AMVP; Occurrence of major cardiac events in AMVP; Occurrence of major cardiac events in PPCM; Occurrence of major cardiac events in PPCM; Occurrence of major cardiac events in PPCM; Occurrence of major cardiac events in PPCM; Occurrence of major cardiac events in AFD; Occurrence of major cardiac events in AFD; Occurrence of major cardiac events in AFD; Occurrence of major cardiac events in AFD; Occurrence of major cardiac events in storage and dysmetabolic diseases; Occurrence of major cardiac events in storage and dysmetabolic diseases; Occurrence of major cardiac events in storage and dysmetabolic diseases; Occurrence of major cardiac events in storage and dysmetabolic diseases; Occurrence of major cardiac events in mitochondrial diseases; Occurrence of major cardiac events in mitochondrial diseases; Occurrence of major cardiac events in mitochondrial diseases; Occurrence of major cardiac events in mitochondrial diseases; Occurrence of major cardiac events in channelopathies with structural changeschannelopathies with structural changes; Occurrence of major cardiac events in channelopathies with structural changes; Occurrence of major cardiac events in channelopathies with structural changes; Occurrence of major cardiac events in channelopathies with structural changes; Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Occurrence of major cardiac events in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Occurrence of major cardiac events in overlapping phenotypes; Occurrence of major cardiac events in overlapping phenotypes; Occurrence of major cardiac events in overlapping phenotypes; Occurrence of major cardiac events in overlapping phenotypes; Occurrence of major cardiac events in undefined phenotypes; Occurrence of major cardiac events in undefined phenotypes; Occurrence of major cardiac events in undefined phenotypes; Occurrence of major cardiac events in undefined phenotypes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in DCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in HCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in RCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in ACM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in LVNC; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AMVP; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in PPCM; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in AFD; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in storage and dysmetabolic diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in mitochondrial diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in channelopathies with structural changes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in cardiomyopathies associated with systemic rheumatologic or neuromuscular diseases; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in overlapping phenotypes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes; Evaluation of efficacy of treatment, defined based on the incidence of major events during follow-up in undefined phenotypes